Fujifilm to end delayed Avigan clinical trials in Japan in Sept.

Fujifilm Holdings Corp. said Thursday it expects to complete clinical tests in Japan of the antiviral drug Avigan, a potential candidate treatment for COVID-19, in September, after a delay caused by difficulty in securing enough patient data.The last patient will participate in the clinical study on Sunday and all necessary data will have been collected a month later, Fujifilm director Junji Okada said.Related coverage:Philippines says nation has yet to start Avigan clinical trialFujifilm to start clinical study of COVID-19 drug Avigan in KuwaitREAD FULL ARTICLE